As of Dec 20, 2024, the Sarepta Therapeutics stock's PE ratio is 76.26. This results from the current EPS of $1.56 and stock price of $118.97.
Year | PE ratio | Change |
---|---|---|
2023 | N/A | N/A |
2022 | N/A | N/A |
2021 | N/A | N/A |
2020 | N/A | N/A |
2019 | N/A | N/A |
2018 | N/A | N/A |
2017 | N/A | N/A |
2016 | N/A | N/A |
2015 | N/A | N/A |
2014 | N/A | N/A |
Compared to its peer stock GILD, SRPT's PE ratio stands lower.
Stock name | PE ratio | Market cap |
---|---|---|
SRPT Sarepta Therapeutics Inc | 76.26 | $11.36B |
GILD Gilead Sciences Inc | 925.7 | $115.37B |
NVAX Novavax Inc | N/A | $1.39B |
PTCT Ptc Therapeutics Inc | N/A | $3.57B |
BCRX Biocryst Pharmaceuticals Inc | N/A | $1.57B |
ALNY Alnylam Pharmaceuticals Inc | N/A | $31.66B |
RNA Avidity Biosciences Inc | N/A | $3.8B |
INSM INSMED Inc | N/A | $12.6B |
The price to earnings ratio for SRPT stock is 76.26 as of Dec 20, 2024.
A company with a higher PE ratio may indicate that the market has higher growth expectations for the company's future earnings or profitability.
You can calculate the PE ratio by dividing the most recent stock price by the trailing twelve months EPS. As of today (Dec 20, 2024), Sarepta Therapeutics's stock price is $118.97. The earnings per share for the trailing twelve months (TTM) ending Sep 2024 is $1.56. Therefore, Sarepta Therapeutics's P/E ratio for today is 76.26. PE RATIO(76.26) = STOCK PRICE($118.97) / TTM EPS($1.56)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.